Novartis works with many organizations that advocate for patients around the world. These organizations play a crucial role by informing and supporting patients, as well as safeguarding the rights of patients and caregivers. Further, patient organizations provide healthcare companies with important advice from their own perspective. Interacting with patient organizations enables Novartis to learn about and understand unmet patient needs, as well as barriers to treatment success. This information can guide us in developing therapies and solutions that effectively address these needs.
In all our interactions with patient groups, we are committed to working ethically and transparently while respecting their integrity. Novartis fully complies with all legal and statutory requirements regarding the disclosure of patient group support as a minimum standard in any country.
Novartis discloses our relationships with patient organizations by March 31 every year, in compliance with the Code of Practice on Relationships between the Pharmaceutical Industry and Patient Organizations set by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Novartis fully recognizes that it has many common interests with patient organizations that represent and support the needs of patients and their caregivers. Novartis endorses the EFPIA Code ensuring that its relationships with patient organizations take place in an ethical and transparent manner.